Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graves Ophthalmopathy | 2 | 2022 | 9 | 0.930 |
Why?
|
| Exophthalmos | 2 | 2022 | 18 | 0.920 |
Why?
|
| Eyelid Diseases | 2 | 2022 | 18 | 0.900 |
Why?
|
| Drug Costs | 2 | 2016 | 100 | 0.900 |
Why?
|
| Eye Diseases | 3 | 2021 | 82 | 0.820 |
Why?
|
| Health Care Costs | 2 | 2016 | 367 | 0.780 |
Why?
|
| Ophthalmologists | 2 | 2020 | 12 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 1274 | 0.590 |
Why?
|
| Methotrexate | 2 | 2016 | 249 | 0.590 |
Why?
|
| Hemifacial Spasm | 1 | 2018 | 2 | 0.580 |
Why?
|
| Blepharospasm | 1 | 2018 | 7 | 0.580 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 39 | 0.550 |
Why?
|
| Rheumatologists | 1 | 2016 | 15 | 0.530 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 18 | 0.520 |
Why?
|
| Azathioprine | 1 | 2016 | 50 | 0.520 |
Why?
|
| Insurance, Health | 2 | 2016 | 269 | 0.500 |
Why?
|
| Arthritis, Juvenile | 1 | 2016 | 53 | 0.490 |
Why?
|
| Vision Disorders | 1 | 2016 | 135 | 0.470 |
Why?
|
| Glucocorticoids | 2 | 2016 | 582 | 0.470 |
Why?
|
| Uveitis | 1 | 2016 | 127 | 0.470 |
Why?
|
| Uveitis, Posterior | 1 | 2014 | 12 | 0.460 |
Why?
|
| Uveitis, Intermediate | 1 | 2014 | 8 | 0.460 |
Why?
|
| Eyelid Neoplasms | 2 | 2024 | 9 | 0.410 |
Why?
|
| Ophthalmology | 3 | 2020 | 82 | 0.260 |
Why?
|
| Specialization | 2 | 2016 | 145 | 0.220 |
Why?
|
| Mohs Surgery | 1 | 2024 | 25 | 0.220 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2024 | 74 | 0.200 |
Why?
|
| Eye Hemorrhage | 1 | 2022 | 1 | 0.200 |
Why?
|
| Electronic Health Records | 2 | 2020 | 979 | 0.200 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2022 | 2 | 0.200 |
Why?
|
| Surgical Flaps | 1 | 2024 | 136 | 0.200 |
Why?
|
| Keratitis | 1 | 2022 | 14 | 0.190 |
Why?
|
| Blepharitis | 1 | 2022 | 5 | 0.190 |
Why?
|
| Ophthalmoplegia | 1 | 2021 | 8 | 0.180 |
Why?
|
| Cavernous Sinus | 1 | 2021 | 17 | 0.180 |
Why?
|
| Trochlear Nerve Diseases | 1 | 2021 | 7 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 858 | 0.180 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2021 | 9 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Population Health | 1 | 2021 | 46 | 0.180 |
Why?
|
| Orbital Diseases | 1 | 2021 | 28 | 0.180 |
Why?
|
| Coinfection | 1 | 2021 | 131 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 5437 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 226 | 0.150 |
Why?
|
| Decision Making | 2 | 2016 | 864 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 207 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 532 | 0.140 |
Why?
|
| Injections | 1 | 2018 | 174 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2016 | 147 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 756 | 0.130 |
Why?
|
| Humans | 15 | 2024 | 129847 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2020 | 735 | 0.120 |
Why?
|
| Rheumatology | 1 | 2016 | 107 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 830 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2016 | 558 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 304 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 660 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 495 | 0.100 |
Why?
|
| United States | 3 | 2021 | 13913 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2016 | 603 | 0.090 |
Why?
|
| Female | 6 | 2024 | 68829 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2024 | 14553 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1920 | 0.080 |
Why?
|
| Middle Aged | 3 | 2021 | 31177 | 0.080 |
Why?
|
| Patient Satisfaction | 2 | 2024 | 639 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 7158 | 0.070 |
Why?
|
| Male | 4 | 2024 | 63759 | 0.060 |
Why?
|
| Adult | 2 | 2021 | 35634 | 0.060 |
Why?
|
| Blepharoplasty | 1 | 2024 | 8 | 0.060 |
Why?
|
| Eyelids | 1 | 2024 | 34 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 5085 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 24 | 0.050 |
Why?
|
| Oculomotor Muscles | 1 | 2022 | 38 | 0.050 |
Why?
|
| Adolescent | 1 | 2021 | 20451 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 307 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 10 | 0.050 |
Why?
|
| Ketosis | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 154 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2021 | 300 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 168 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 388 | 0.040 |
Why?
|
| Sinusitis | 1 | 2021 | 211 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 185 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 680 | 0.040 |
Why?
|
| Child | 1 | 2016 | 20962 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1161 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 22107 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1020 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3089 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 7066 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2511 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 10241 | 0.020 |
Why?
|